Previous studies have reported differences in the prognostic value of Sp1 overexpression in breast and lung cancer patients and also differences in the pro- and anti-carcinogenic role of Sp1 in MDA-MB-231 breast and A549 lung cancer cell lines [10, 43–47]. This evidence concerns the gene SP1 and lung cancer.